Clinical trials: Atopic Dermatitis (Eczema)
Eczema, Dermatitis, Atopic
Integrative Body-Mind-Spirit Intervention for Families With Children Suffering From Eczema
This randomized controlled trial aims to examine the efficacy of two integrative body-mind-spirit interventions, compared to a health education active control, in promoting adaptive emotional regulation and quality of life of…
- Trial name
- NCT04617977
- Testing
- I-BMS for families with children suffering from eczema, Health education for parents whose children have eczema
- Where
- Hong Kong
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Atopic Dermatitis
JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis
This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to <18 years of age with moderate to severe AD.
- Trial name
- JADE TEEN (NCT03796676)
- Testing
- PF-04965842, PF04965842
- Where
- 136 sites in United States, Australia and 12 more
- Volunteers
- 287 people
- Sponsor
- Pfizer
Atopic Dermatitis
Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
This is a Randomized, Double-blind, Vehicle-Controlled, Seamless and Adaptive-designed Phase II/III Study to Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Adult Patients with Mild-to-Moderate Atopic Dermatitis.
- Trial name
- MARBLE-23 (NCT04717310)
- Testing
- SHR0302 Ointment, Vehicle
- Where
- 31 sites in China
- Volunteers
- 645 people
- Sponsor
- Reistone Biopharma Company Limited
Dermatitis, Atopic
Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment
Long-term tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat active lesions of atopic dermatitis and prevent…
- Trial name
- NCT00480610
- Testing
- tacrolimus ointment
- Where
- 22 sites in Austria, Belgium and 11 more
- Volunteers
- 226 people
- Sponsor
- Astellas Pharma Inc
Atopic Dermatitis
Creation of a Shared Medical Decision-making Tool for Atopic Dermatitis
Hypothesis/Objective : Patient-centered health care and shared decision making are key components of increasing importance which are recommended by the French Haute Autorite de Sante (HAS) and World Health Organization (WHO).
- Trial name
- SHADOW (NCT05090982)
- Testing
- Audio recordings during the consultations, Audio recordings during the consultations and test of the shared medical decision-making tool for modification, Audio recordings during the consultations and test of the shared medical decision-making tool for validation
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atopic Dermatitis, Eczema Atopic Dermatitis
Real-World Study on the Impact of Atopic Dermatitis From a Caregiver Perspective
This study will address this gap by providing comprehensive data on disease burden from a caregiver perspective in a Canadian population, ultimately supporting improved clinical decision-making and healthcare resource allocation.
- Conditions
- Atopic Dermatitis, Eczema Atopic Dermatitis, Eczema, Caregiver
- Trial name
- NCT07323394
- Testing
- No Intervention: Observational Cohort
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- PeriPharm
Atopic Dermatitis
A First-in-Human Study of CEE321 in Adult Subjects
Open label, non-randomized, uncontrolled, First-in-Human Phase 1 Study in Healthy Subjects and Subjects with Atopic Dermatitis
- Trial name
- NCT04612062
- Testing
- CEE321
- Where
- 3 sites in United States, Japan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis
The purpose of this study is to determine if an asynchronous online model of teledermatology can achieve similar clinical outcomes as compared to conventional in-office care for the management of atopic dermatitis.
- Trial name
- NCT00985894
- Testing
- Online Teledermatology Care, Conventional in Office Care
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- University of California, Davis
Atopic Dermatitis
SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects
RBN-3143 Background: PARP proteins are members of a family of seventeen ADP-ribosyltransferase (ART) enzymes that regulate cellular processes including gene expression, protein degradation, and multiple cellular stress responses.
- Trial name
- NCT05215808
- Testing
- RBN-3143
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ribon Therapeutics, Inc.
Atopic Dermatitis
Effects of Abrocitinib Treatment on Skin Barrier Function
Effects of abrocitinib treatment of atopic dermatitis on skin barrier function.
- Trial name
- AbroSkib (NCT05140239)
- Testing
- No Intervention
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Prof. Dr. Stephan Weidinger
Atopic Dermatitis
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis
The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneously using devices for injection.
- Trial name
- ROCKET-Outpost (NCT06224192)
- Testing
- Rocatinlimab Prefilled Syringe, Rocatinlimab AI
- Where
- 47 sites in United States, Canada and 2 more
- Volunteers
- 151 people
- Sponsor
- Amgen
Atopic Dermatitis
Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis
Atopic dermatitis, which is also known as atopic eczema, is a common inflammatory and chronic skin disease that is characterized by severe recurrent erythematous and pruritic lesions.
- Trial name
- NCT05969730
- Testing
- Baricitinib 4 MG, Azathioprine 1.5-2.5 mg/kg
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Mazandaran University of Medical Sciences
Hand Eczema
Dupilumab in Severe Chronic Hand Eczema
The purpose of this study is to investigate the efficacy of dupilumab in hand eczema patients with an inadequate response or intolerance to alitretinoin.
- Trial name
- DUPSHE (NCT04512339)
- Testing
- Dupilumab
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- University Medical Center Groningen
Dermatologic Disease
A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone
One of the most frequent skin conditions is atopic dermatitis (AD), characterized by its pruritic inflammation effect. Where the prevalence of AD increased in the last three decades by two or three folds worldwide, especially in…
- Trial name
- NCT05607901
- Testing
- Tacrolimus ointment, Hydrocortisone 1% cream
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Tanta University
Atopic Dermatitis
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
- Trial name
- ROCKET-ASCEND (NCT05882877)
- Testing
- Rocatinlimab
- Where
- 547 sites in United States, Argentina and 40 more
- Volunteers
- 2,621 people
- Sponsor
- Amgen
Atopic Dermatitis
Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
To demonstrate the superiority of the investigational medicinal product (IMP; 0.3% OPA-15406 ointment, 1% OPA-15406 ointment, or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in…
- Trial name
- NCT03911401
- Testing
- 0.3% OPA-15406, 1% OPA-15406
- Where
- Japan
- Volunteers
- 251 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Dermatitis, Eczema
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to <18 years of age with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADorable-1 (NCT05559359)
- Testing
- Lebrikizumab, Topical Corticosteroid (TCS)
- Where
- 85 sites in United States, Argentina and 10 more
- Volunteers
- 377 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis
Part 1: To investigate the safety and tolerability of intravenous (IV) or subcutaneous (SC) administration of a single dose of KHK4323 to Japanese or Caucasian healthy adult males in a double-blind, placebo-controlled study.
- Trial name
- NCT03846466
- Testing
- KHK4323 IV/S, KHK4323 SC/S, KHK4323 IV/M
- Where
- Japan
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Mild to Moderate Atopic Dermatitis
A Controlled Study to Evaluate the Efficacy and the Tolerability of a Cosmetic Active Ingredient Intended for Subjects With Atopic Dermatitis
Evaluation of safety and clinical efficacy of an active ingredient versus placebo for the treatment of mild to moderate Atopic Dermatitis (AD) adults.
- Trial name
- NCT05057351
- Testing
- Isopentenyltheophylline 0.44% + Glycerin 4.56%, Glycerin 4.56%
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Greenpharma S.A.S.
Atopic Eczema
A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema
A 4 week, open label, multi-centre (GP setting), post market clinical follow-up study with Doublebase Once in patients of any age and any severity of atopic eczema.
- Trial name
- NCT06453512
- Testing
- Doublebase Once
- Where
- United Kingdom
- Volunteers
- 65 people
- Sponsor
- Dermal Laboratories Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.